The earlier bremelanotide dose-finding report should not be substituted for the later RECONNECT trials. Its reported pooled comparison also should not be assigned to every individual study group. Primary trial
Study snapshot
Premenopausal women with sexual dysfunction were randomized to placebo or one of three bremelanotide groups over 12 weeks. The abstract reports efficacy data for 327 participants. Satisfying sexual events per month were the primary endpoint; sexual-function and distress scales were secondary measures. A pooled comparison of two active groups favored bremelanotide. Nausea, flushing, and headache were reported adverse events. The study registration is NCT01382719. Primary trial
Our appraisal: a pooled estimate has a defined membership
When groups are combined, the resulting estimate describes that combination under the analysis used. It does not establish an identical result in each constituent group or in a group excluded from the pool. A summary should state which comparison it is discussing, even when it omits technical dose details.
For a hypothetical example, two active groups could have different response sizes yet yield a favorable pooled estimate. That would not make their separate estimates equal. Whether pooling was planned, how it was weighted, and what question it was intended to answer are therefore useful full-paper checks.
Outcomes need their own labels
An event count, a sexual-function scale, and a distress scale do not use the same unit. Improvement in one cannot be expressed as though it were a change in another. Our review should preserve whether the estimate is a change from baseline or a difference in changes between groups.
Before release, inspect the analysis population, completion and withdrawal counts, endpoint hierarchy, multiplicity handling, and full safety findings. The abstract's efficacy sample should not be silently relabeled as everyone randomized without checking participant flow.
Frequently asked questions
Is this the phase 3 RECONNECT publication?
No. It is the separate dose-finding study registered as NCT01382719.
Does a pooled result describe each group individually?
No. Separate group estimates must be checked separately.
Were all outcomes counts of sexual events?
No. The study also used function and distress questionnaires.
Does the abstract's efficacy count establish total enrollment?
Not without reconciling the participant-flow information.
Can adverse events be omitted from an efficacy summary?
Doing so would give an incomplete picture; benefits and harms need separate attention.
Does this validate a product sold as PT-141?
A shared name does not establish identity, formulation equivalence, or suitability for use.
What is this page's scope?
A primary-abstract-based historical appraisal, not current prescribing guidance or a treatment schedule.